GSK completes production-line upgrade; U.K. to boost Big Pharma appeal;

> GlaxoSmithKline ($GSK) has completed a three-year, $7-million upgrade of two production lines at a plant in Brasov, Romania. Item

> BioMarin Pharmaceutical will double the capacity of its Novato, CA, plant to produce $1 billion in products, including biggest seller Naglazyme. Item

> Six drug-delivery technologies are helping drugmakers extend patents: affinity-based targeting, controlled/sustained-release systems, passive delivery, active device delivery, passive device delivery and processing technologies. Release

> Tanzania is set to begin production of generic antiretroviral drugs in a new multi-million-dollar manufacturing plant in Arusha. Story

> Vivimed Labs of Hyderabad, India, has acquired Uquifa, a manufacturer of APIs and intermediates with operations in Spain and Mexico. Article

> Norbert Dentressangle has opened a shared-user cold store facility in the south of France. Story

> A groundbreaking ceremony on Friday signaled the construction start of a $394 million Chengdu, Sichuan, China cold-chain logistics center, which will boast 160,000 square meters of distribution space. Article

> The U.K.'s FDS Pharma has acquired the Rehovot hepatitis vaccine manufacturing plant of SciGen Israel for $2 million plus 5% royalties on sales. Story

> Millstone Medical Outsourcing said it will provide freezer storage and cold chain distribution services for customers' biologic products from a Memphis, TN-based facility. Story

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.